In the latest development regarding insider activity at Protagonist Therapeutics, Inc. (NASDAQ: PTGX), director William D. Waddill has completed a substantial divestment of company shares. On June 23, 2026, Waddill sold 9,000 shares of the firm's common stock. The transaction resulted in a total value of $1,061,460, executed at share prices fluctuating between $117.00 and $119.07. The weighted average price for this sale was calculated at $117.94 per share.
This specific transaction was facilitated through a pre-arranged 10b5-1 trading plan. Mr. Waddill originally adopted this plan on February 27, 2026, establishing a predetermined schedule for trading activities independent of subsequent market fluctuations or material non-public information.
Concurrently with the sale of the 9,000 shares, Mr. Waddill engaged in the acquisition of an equal number of shares through the exercise of stock options. These 9,000 shares were acquired at a price of $16.54 per share, totaling $148,860. The documentation indicates that these stock options were fully vested at the precise time of exercise, confirming the eligibility of the transaction under company equity guidelines.
Following the completion of these dual transactions, Mr. Waddill's direct ownership stake in Protagonist Therapeutics stands at 7,825 shares of common stock. This remaining holding reflects the net position after the offsetting sale and option exercise activities.
The insider transaction occurs against a backdrop of robust market performance for PTGX. The stock is currently trading at $122.63, a level that places it in close proximity to its 52-week high of $124.80. Over the preceding twelve-month period, the stock has delivered a remarkable 124% return, underscoring significant investor interest and valuation expansion.
According to analysis from InvestingPro, the current valuation of PTGX appears overvalued relative to its calculated Fair Value. Investors utilizing InvestingPro subscriptions have access to 19 additional exclusive tips regarding PTGX, which include detailed profitability forecasts and comprehensive valuation metrics designed to assist in investment decision-making.
In the broader context of analyst sentiment, Protagonist Therapeutics has been the subject of recent notable actions from several financial institutions. Wolfe Research recently initiated coverage on the company, assigning an outperform rating. The firm highlighted the strength of Protagonist's early-stage pipeline and established a price target of $135.
BMO Capital has reiterated its outperform rating on PTGX, emphasizing the momentum generated from recent commercial launches and anticipated regulatory approvals. BMO has set a price target of $112 for the stock.
Citizens increased its price target to $137 while maintaining a market outperform rating. The firm noted the validation of Protagonist's peptide platform, specifically citing the approval of Icotyde for the treatment of psoriasis as a key factor in their positive outlook.
Jefferies also reiterated a buy rating, setting a price target of $121. The firm pointed to Johnson & Johnson's positive outlook on Icotyde, projecting the product as one of its largest potential assets with sales exceeding $10 billion.
Truist Securities raised its price target to $121, maintaining a buy rating. Truist cited Johnson & Johnson's report regarding the rapid access and uptake of Icotyde in treating psoriasis, further validating the commercial trajectory of the partnership.
These collective analyst developments highlight Protagonist Therapeutics' growing recognition within the industry and the increasing scrutiny placed on its commercial execution and pipeline potential.